Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.
Delage L, Lambert M, Bardel É, Kundlacz C, Chartoire D, Conchon A, Peugnet AL, Gorka L, Auberger P, Jacquel A, Soussain C, Destaing O, Delecluse HJ, Delecluse S, Merabet S, Traverse-Glehen A, Salles G, Bachy E, Billaud M, Ghesquières H, Genestier L, Rouault JP, Sujobert P. Delage L, et al. Among authors: lambert m. Blood. 2023 Mar 9;141(10):1209-1220. doi: 10.1182/blood.2022016943. Blood. 2023. PMID: 36375119 Free article.
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M, Kosmider O, Radford-Weiss I, Moura IC, Auberger P, Ifrah N, Bardet V, Chapuis N, Lacombe C, Mayeux P, Tamburini J, Bouscary D. Willems L, et al. Among authors: lambert m. Blood. 2013 Nov 14;122(20):3521-32. doi: 10.1182/blood-2013-03-493163. Epub 2013 Sep 6. Blood. 2013. PMID: 24014241 Free PMC article.
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N, Ronchetti AM, Larrue C, Meunier G, Birsen R, Willems L, Saland E, Decroocq J, Maciel TT, Lambert M, Poulain L, Hospital MA, Sujobert P, Joseph L, Chapuis N, Lacombe C, Moura IC, Demo S, Sarry JE, Recher C, Mayeux P, Tamburini J, Bouscary D. Jacque N, et al. Among authors: lambert m. Blood. 2015 Sep 10;126(11):1346-56. doi: 10.1182/blood-2015-01-621870. Epub 2015 Jul 17. Blood. 2015. PMID: 26186940 Free PMC article.
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia.
Grenier A, Poulain L, Mondesir J, Jacquel A, Bosc C, Stuani L, Mouche S, Larrue C, Sahal A, Birsen R, Ghesquier V, Decroocq J, Mazed F, Lambert M, Andrianteranagna M, Viollet B, Auberger P, Lane AA, Sujobert P, Bouscary D, Sarry JE, Tamburini J. Grenier A, et al. Among authors: lambert m. Cell Rep. 2022 Jan 4;38(1):110197. doi: 10.1016/j.celrep.2021.110197. Cell Rep. 2022. PMID: 34986346 Free article.
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J. Hospital MA, et al. Among authors: lambert m. Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15. Leukemia. 2018. PMID: 28914261
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Green AS, et al. Among authors: lambert m. Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep. Sci Adv. 2015. PMID: 26601252 Free PMC article.
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Green AS, et al. Among authors: lambert m. Blood. 2010 Nov 18;116(20):4262-73. doi: 10.1182/blood-2010-02-269837. Epub 2010 Jul 28. Blood. 2010. PMID: 20668229 Free article.
A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties.
Dahmani R, Just PA, Delay A, Canal F, Finzi L, Prip-Buus C, Lambert M, Sujobert P, Buchet-Poyau K, Miller E, Cavard C, Marmier S, Terris B, Billaud M, Perret C. Dahmani R, et al. Among authors: lambert m. Oncogene. 2015 Apr 30;34(18):2337-46. doi: 10.1038/onc.2014.182. Epub 2014 Jul 7. Oncogene. 2015. PMID: 24998845
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.
Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N. Poulain L, et al. Among authors: lambert m. Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10. Leukemia. 2017. PMID: 28280275
2,680 results